Gilead Sciences PESTLE Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Gilead Sciences
Skip the Research. Get the Strategy.
Gilead Sciences faces a complex external landscape—regulatory scrutiny, shifting drug-pricing debates, advancing biotech technologies, and growing ESG expectations—that could reshape its R&D and market strategies; our PESTLE distills these forces into actionable intelligence. Purchase the full analysis to get detailed risk scenarios, strategic implications, and ready-to-use slides to inform investment or corporate decisions.
Political factors
Drug Pricing Legislation and the Inflation Reduction Act
The ongoing implementation of the Inflation Reduction Act (IRA) is pressuring Gilead’s pricing strategy, as Medicare negotiation could target top antiviral drugs that accounted for roughly $13.5B of revenue in 2024; negotiated price caps may compress gross margins on established products.
Geopolitical Stability and Global Supply Chain Security
Trade tensions between the US, EU and China risk disrupting supply of APIs and intermediates; in 2024 global pharma trade volatility rose 12%, increasing procurement costs for firms like Gilead that sourced ~35% of APIs from Asia in 2023. Gilead’s network spans 20+ countries and remains sensitive to shifts in tariffs and export controls that can delay production. Strategic diversification—Gilead expanded capacity with a $500m investment in 2024 to add sites in Ireland and Singapore—mitigates regional political instability risks.
Government Funding for HIV and Hepatitis Initiatives
Public health budgets and programs like PEPFAR (FY2025 US appropriations ~$6.8bn) materially drive demand for Gilead antiviral sales, with PEPFAR and the Global Fund supporting procurement in >50 low- and middle-income countries.
Shifts in political leadership or fiscal priorities can cut yearly allocations—PEPFAR funding varied ±5–10% over past decade—creating revenue volatility for Gilead in key markets.
Maintaining access requires sustained advocacy and public-private partnerships; Gilead reported ~$1.2bn in global access investments in 2024 to secure procurement channels and tiered pricing.
Regulatory Alignment Across International Markets
Political cooperation on healthcare standards accelerates Gilead’s global launch of oncology and inflammation drugs; harmonized approvals cut time-to-market—EMA median approval 426 days vs FDA 303 days (2023), while China’s NMPA reforms reduced review times by ~20% in 2021–2023.
Divergent EU, US, China requirements raise compliance costs—Gilead reported R&D and licensing expenses of $6.2bn in FY2024—risking delayed revenue recognition and market fragmentation.
Gilead must align regulatory strategies across jurisdictions through parallel submissions and reliance pathways to optimize rollout and protect peak sales.
- FDA median approval 303 days (2023) vs EMA 426 days
- China NMPA review times down ~20% (2021–2023)
- Gilead R&D/licensing expenses $6.2bn FY2024
Taxation Policies and International Profit Repatriation
Corporate tax reforms in the US and the OECD two-pillar global minimum tax (15%) affect Gilead’s effective tax rate and cash repatriation strategies; Gilead reported a GAAP tax rate of 12% in 2024 but faces pressure to align with the 15% minimum, which could reduce tax planning opportunities and increase cash tax outflows.
Revisions to IP taxation—shift toward nexus-based and marketing-relief rules—can lower after-tax margins on overseas royalties; in 2024 Gilead booked ~30% of revenue outside the US, so changes materially affect net profitability by region.
Financial planners must model increased cash taxes and reduced BEPS-driven benefits when valuing Gilead; sensitivity scenarios shifting the effective tax rate by +3–6 percentage points can reduce FCFF and terminal value meaningfully for DCFs.
- 2024 GAAP tax rate: 12%
- OECD global minimum: 15%
- ~30% revenue from outside US (2024)
- Valuation sensitivity: +3–6 ppt tax rate → lower FCFF/terminal value
Gilead faces pricing, tax & supply risks—$13.5B antiviral revenue and margin pressure
Political actions—IRA Medicare negotiation, OECD 15% minimum tax, and trade/tariff shifts—threaten Gilead’s pricing, margins, and supply chain; IRA targets ~$13.5B antiviral revenue (2024), GAAP tax 12% vs OECD 15%, ~30% revenue outside US, and 35% APIs sourced from Asia (2023). Gilead’s $500m 2024 capacity spend and $1.2bn access investments partially mitigate risks while regulatory divergence raises R&D/compliance costs ($6.2bn FY2024).
| Metric | Value |
|---|---|
| Antiviral revenue at risk (2024) | $13.5B |
| GAAP tax rate (2024) | 12% |
| OECD minimum tax | 15% |
| Revenue outside US (2024) | ~30% |
| APIs from Asia (2023) | 35% |
| 2024 capacity investment | $500M |
| 2024 access investments | $1.2B |
| R&D/licensing expense (FY2024) | $6.2B |
What is included in the product
Detailed Word Document
Explores how external macro-environmental factors uniquely affect Gilead Sciences across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to inform strategy, risk mitigation, and opportunity identification for executives and investors.
Customizable Excel Spreadsheet
A concise, visually segmented PESTLE snapshot of Gilead Sciences that highlights regulatory, technological, and market risks for quick inclusion in decks or meeting briefs, with editable notes for regional or pipeline-specific context.
Economic factors
Impact of Global Interest Rate Environments
Persistent high US Federal Reserve rates (2024 year-end federal funds target 5.25–5.50%) and 10-year Treasury yields around 4.6% increase Gilead Sciences’ cost of debt, raising financing costs for oncology M&A and potentially reducing deal IRRs.
Higher rates make leverage pricier; Gilead’s net debt/EBITDA (about 1.5x FY2024) and $7–8bn annual cash flow projections shape its ability to fund acquisitions without excessive dilution.
Investors should monitor credit spreads and Fed guidance, as rate volatility can constrain deal size, push Gilead toward stock-based trades, or delay strategic expansion.
Currency Exchange Rate Volatility
With approximately 45% of 2024 revenue derived outside the US, Gilead faces material exposure to US dollar movements; a 10% dollar appreciation versus major currencies historically reduced reported international revenue by roughly 4–6% in prior periods.
Healthcare Budget Constraints and Payor Pressure
Economic downturns and 2024–25 austerity measures have tightened reimbursement: OECD government health spending growth slowed to 1.2% in 2024, prompting stricter payor reviews across Europe and parts of Asia.
Insurers now demand demonstrable long-term value; US private payors rejected or limited access to several high-cost cell therapies in 2024 after cost-effectiveness concerns.
Gilead must prove superior cost-effectiveness—health economic models showing lower lifetime costs or QALY gains versus standard care are increasingly required to secure coverage and favorable pricing.
Inflationary Pressure on Manufacturing and R&D Costs
Inflation has driven wages for specialized biotech talent up ~6-8% in 2024 and raw-material costs rise ~9% year-over-year, compressing Gilead’s operating margins unless drug prices or efficiency gains offset them.
The capital-intensive R&D budget is sensitive to inflation; a 5% CPI rise in 2024 can increase pipeline costs by hundreds of millions, affecting future approvals.
Operational efficiency and supply-chain optimization—including hedging energy and sourcing strategies—are essential to protect profitability.
- Specialized labor +6–8% (2024)
- Raw materials +9% YoY (2024)
- CPI impact ~5% raises pipeline costs materially
- Focus: supply-chain, energy hedging, operational efficiency
Consumer Purchasing Power in Emerging Markets
Rising middle classes in markets like India and Brazil—where middle-class consumption grew by ~3% CAGR 2015–2023 and middle-class populations reached ~300m and ~110m respectively in 2024—increase demand for Gilead’s antivirals and HIV treatments but affordability remains constrained.
Economic volatility, with 2023 GDP growth swings of ±2–4% in many EMs, can suppress uptake of high-cost chronic therapies, pressuring volumes and reimbursement timelines.
Tiered pricing and local manufacturing partnerships are essential; Gilead has used differential pricing in ~40+ LMICs and can expand such models to protect margins while boosting access.
- Rising middle class: India ~300m, Brazil ~110m (2024)
- EM GDP volatility: ±2–4% swings (2023)
- Tiered pricing used in 40+ LMICs
High US rates squeeze oncology M&A returns; FX and input inflation pressure growth
High US rates (Fed funds 5.25–5.50% end-2024) raise funding costs, pressuring oncology M&A returns; net debt/EBITDA ~1.5x and $7–8bn annual cash flow guide deal capacity. FX: ~45% revenue ex-US; a 10% USD appreciation cuts reported intl revenue ~4–6%. 2024: specialized labor +6–8%, raw materials +9% YoY; OECD health spending growth 1.2% tightening reimbursement; EM middle class: India ~300m, Brazil ~110m.
| Metric | 2024 Value |
|---|---|
| Fed funds | 5.25–5.50% |
| 10yr US Treasury | ~4.6% |
| Net debt/EBITDA | ~1.5x |
| Annual cash flow | $7–8bn |
| Revenue ex-US | ~45% |
| Labor inflation | +6–8% |
| Raw materials | +9% YoY |
| OECD health spend growth | 1.2% |
| India middle class | ~300m |
| Brazil middle class | ~110m |
Preview Before You Purchase
Gilead Sciences PESTLE Analysis
The preview shown here is the exact Gilead Sciences PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use. It includes the complete political, economic, social, technological, legal, and environmental assessment as displayed. No placeholders or teasers—this is the real, final document you’ll download immediately after payment. The content and structure are identical to the delivered file.
Sociological factors
Aging Global Demographics and Disease Prevalence
The global population aged 65+ reached about 741 million in 2024 and is projected to exceed 1.5 billion by 2050, driving higher demand for oncology and chronic viral infection treatments relevant to Gilead Sciences. Rising life expectancy and age-related comorbidities expand the addressable market for Gilead’s antiviral and oncology portfolio, supporting revenue resilience—Gilead reported $27.3 billion in product sales in 2024. This demographic trend offers a sustained tailwind for Gilead’s specialized medicines segments.
Social Stigma and Awareness of HIV Prevention
Societal stigma around HIV and awareness of PrEP heavily affect uptake of Gilead’s antiviral portfolio; global PrEP users rose to ~1.2 million in 2023, yet coverage gaps persist in key markets. Education and community outreach funding correlate with higher prescriptions—Gilead invested over $200M in prevention initiatives 2021–2024. Rising acceptance of proactive care supports revenue resilience for Gilead’s HIV franchise, which generated $6.8B in 2024.
Patient Advocacy and Influence on Drug Access
Strong patient advocacy groups, such as HIV/AIDS and hepatitis C networks that influenced access to Gilead therapies, helped expand treatment uptake—Gilead reported 2024 revenues of $28.9B largely driven by antivirals—underscoring advocates' market impact.
Gilead’s collaborations with these organizations guide R&D priorities and patient-centric trials, aligning pipeline decisions with community needs and improving uptake metrics in priority populations.
Maintaining trust with advocates preserves brand loyalty and mitigates access risks, which is critical as payer and regulatory scrutiny grows globally.
Shift Toward Personalized and Precision Medicine
The sociological shift toward personalized medicine—driven by patient demand for genetic-tailored treatments—pushes Gilead to expand diagnostics and targeted oncology pipelines; in 2025 Gilead increased R&D oncology spending to about $1.2B, reflecting this pivot.
Adapting to a patient-centric model is essential: precision therapies now command higher pricing and uptake, with genomically guided cancer therapies growing ~14% CAGR through 2024–25, impacting Gilead’s strategy and partnerships.
- R&D oncology spend ~ $1.2B (2025)
- Genomic-guided cancer therapies growth ~14% CAGR (2024–25)
- Requires investment in diagnostics and companion tests
Focus on Health Equity and Global Access
Social pressure is rising for pharma to reduce health disparities; 2024 surveys show 68% of global consumers expect equitable access from major drugmakers, pushing Gilead to expand licensing and tiered pricing for HIV and hepatitis therapies.
Gilead’s voluntary licensing and access programs reached 100+ low- and middle-income countries by 2025, but critics cite gaps in affordability, risking reputational harm and scrutiny from regulators and NGOs.
- 68% consumers expect equitable access (2024)
- 100+ LMICs covered by Gilead licenses (by 2025)
- Failure to act → reputational damage and regulatory scrutiny
Aging Populations and Equity Drive Gilead’s $27B+ Growth in Antivirals & Oncology
Aging population (741M 65+ in 2024; >1.5B by 2050) and rising comorbidities expand demand for Gilead’s antivirals/oncology (product sales $27.3B in 2024). PrEP users ~1.2M (2023); HIV franchise $6.8B (2024). Gilead invested ~$1.2B in oncology R&D (2025); voluntary licenses to 100+ LMICs (2025) amid 68% consumer demand for equitable access (2024).
| Metric | Value |
|---|---|
| 65+ population (2024) | 741M |
| Gilead product sales (2024) | $27.3B |
| HIV sales (2024) | $6.8B |
| Oncology R&D (2025) | $1.2B |
| PrEP users (2023) | ~1.2M |
| Licenses in LMICs (2025) | 100+ |
Technological factors
Artificial Intelligence in Drug Discovery and Development
Gilead is integrating AI/ML to speed candidate ID and optimize trial design, citing partnerships and a 2024 internal report showing a 30% reduction in preclinical cycle time and an estimated $120–200m potential cost saving per major program.
Advancements in CAR-T and Cell Therapy Platforms
The evolution of cell therapy, led by Kite Pharma within Gilead, anchors its oncology strategy as CAR-T sales reached about $2.1 billion globally in 2024, with Kite contributing a majority via Yescarta and pipeline candidates. Manufacturing innovations—automated closed systems and allogeneic approaches—have cut production times and aim to reduce per-treatment costs, which currently can exceed $375,000. Continued leadership in genetic engineering and gene-editing partnerships is critical to defend market share amid competitors expanding CAR-T approvals and projected market growth to ~$20 billion by 2030.
Digital Health Integration and Patient Monitoring
Wearables and digital platforms improve monitoring of outcomes and adherence; global digital health market hit about $640B in 2025, supporting richer patient data streams for Gilead.
Gilead can use real-world evidence from these tools to bolster regulatory submissions and value dossiers for payors, reducing time-to-reimbursement and pricing disputes.
Embedding remote monitoring and adherence apps into therapies strengthens patient engagement and differentiates Gilead’s value proposition, potentially improving outcomes and lowering total cost of care.
Next-Generation Antiviral Delivery Systems
Technological breakthroughs in long-acting formulations are shifting HIV care: long-acting injectables reduced dosing frequency from daily to monthly or bimonthly, with CAB+RPV showing ~90% viral suppression at 96 weeks in pivotal trials and contributing to Gilead-relevant market dynamics after GSK/ViiV advances.
Gilead’s investments in injectable platforms aim to improve adherence and quality of life; lower dosing frequency can cut adherence-related treatment failures by an estimated 30% and raise lifetime treatment value per patient.
Maintaining leadership in delivery technology is critical to defend revenue—HIV products face biosimilar pressure as key franchises lose exclusivity; long-acting formulations can extend commercial lifecycle and protect market share against generics.
- Long-acting injectables: ~90% suppression at 96 weeks (trial benchmark)
- Adherence impact: ~30% reduction in adherence-related failures
- Strategic value: extends commercial lifecycle versus generics
Bioprocessing and Advanced Manufacturing Automation
Automated manufacturing at Gilead enables scalable production of complex biologics with consistent quality, supporting launches like trodelvy and remdesivir where biologics/large-molecule capacity grew ~15% in 2024 capacity expansion projects.
Advances in single-use bioreactors and continuous processing cut downstream waste and are estimated to lower long-term COGS by mid-single digits percentage annually.
Capital invested in state-of-the-art facilities—Gilead disclosed ~$1.2B planned manufacturing spend through 2025—positions the company to meet rising global demand across its oncology and antiviral portfolio.
- Scalability: +15% biologics capacity (2024 expansions)
- Cost: mid-single-digit COGS reduction from advanced bioprocessing
- Capex: ~$1.2B manufacturing spend through 2025
Gilead cuts dev time ~30%, boosts biologics +15% with AI, CAR‑T & $1.2B capex
Gilead leverages AI/ML, CAR-T advances, long-acting injectables, digital health and automated biologics manufacturing to cut development time (~30% preclinical), lower COGS (mid-single-digit%), and expand capacity (+15% biologics 2024); capex ~$1.2B through 2025 supports scale amid a $20B CAR-T market by 2030 and $640B digital health trend.
| Metric | Value |
|---|---|
| Preclinical time reduction | ~30% |
| Biologics capacity change (2024) | +15% |
| COGS impact | Mid-single-digit % |
| Manufacturing capex | ~$1.2B (through 2025) |
Legal factors
Patent Expirations and Intellectual Property Protection
Gilead faces ongoing challenges as patents on key HIV and HCV drugs like Stribild and Harvoni have expired or will soon, enabling generic competition that contributed to a 2024 antiviral revenue decline of roughly 18% year-over-year; generic entrants cut prices and market share. The company must aggressively defend IP and pursue new patents on reformulations and long-acting next-generation assets such as lenacapavir to preserve exclusivity. Managing the patent cliff remains central to maintaining long-term revenue stability, with R&D spend at $6.5 billion in 2024 aimed partly at offsetting losses from expirations.
Regulatory Compliance and FDA/EMA Oversight
FDA and EMA safety and efficacy standards determine Gilead's product launch success; for example, FDA review timelines averaged 10 months in 2024, and a major FDA delay can wipe billions off market cap—Gilead's 2023 peak-to-trough stock swing after regulatory news exceeded 15%.
Approval delays or safety recalls materially affect revenue: a single-year blip in Hepatitis C launches previously reduced projected revenues by over $1.2 billion for peers, illustrating downside risk to Gilead's guidance.
Gilead reported spending $1.1 billion on R&D compliance and pharmacovigilance in 2024, reflecting mandatory continuous investment to meet evolving regulatory requirements and protect market reputation.
Antitrust Scrutiny of Mergers and Acquisitions
As Gilead pursues aggressive M&A to diversify beyond antivirals, heightened antitrust scrutiny risks delays or blocks; U.S. and EU authorities challenged roughly 12% of big pharma deals in 2023–2024, raising review timelines by 4–9 months on average. Major targets in oncology and inflammation could trigger remedies or divestitures, impacting deal value—Gilead spent $25.5B on acquisitions in 2019–2024, increasing regulator focus. Navigating evolving competition law is therefore critical to execution.
Product Liability and Litigation Risks
Gilead faces ongoing product-liability and marketing litigation risks typical for biopharma; settlements and defense costs—such as the industry median pharmaceutical litigation settlement of $50–200 million in 2023—can strain reserves and reduce free cash flow (Gilead reported $7.0B cash from operations in 2024).
Proactive risk management, robust pharmacovigilance, and transparent communication of adverse-event data are essential to limit exposure and preserve stakeholder trust.
- Potential high-cost settlements: $50–200M industry median (2023)
- 2024 cash from operations: $7.0B (Gilead)
- Key mitigants: pharmacovigilance, transparent safety reporting, legal reserves
Intellectual Property Rights in Emerging Markets
Enforcing patent rights in regions like India and South Africa remains difficult for Gilead, where compulsory licenses and weaker IP regimes contributed to generic competition for hepatitis C drugs; 2023 revenues from antiviral portfolio fell 6% partly due to pricing pressure in emerging markets.
Compulsory licensing risks unauthorized production—WHO reported 12 notable compulsory licensing events globally by 2024—forcing Gilead to negotiate voluntary licenses or tiered pricing to protect market access and R&D returns.
Gilead must balance robust IP enforcement with global health commitments: in 2024 Gilead expanded voluntary licensing covering over 100 low- and middle-income countries, aiming to safeguard long-term commercial interests while meeting access goals.
- Patent enforcement challenges: India, South Africa—generic competition impacts revenue.
- Compulsory licensing: ~12 events reported by 2024, increases risk of unauthorized production.
- Mitigation: voluntary licensing covering 100+ LMICs (2024), tiered pricing to balance access and returns.
Gilead Faces -18% Antiviral Hit, $6.5B R&D, Regulatory & Antitrust Risks Drive Volatility
Patent expirations (eg Stribild/Harvoni) drove ~18% antiviral revenue decline in 2024; R&D $6.5B and $1.1B compliance spend. FDA review avg 10 months (2024); regulatory delays can swing stock >15%. Antitrust scrutiny rose—12% of big-pharma deals challenged (2023–24); Gilead M&A $25.5B (2019–24). Compulsory licenses ~12 events by 2024; voluntary licenses cover 100+ LMICs.
| Metric | 2024/2023 |
|---|---|
| Antiviral rev change | -18% (2024) |
| R&D | $6.5B (2024) |
| Compliance spend | $1.1B (2024) |
| Cash from ops | $7.0B (2024) |
Environmental factors
Carbon Footprint Reduction and Sustainability Goals
Gilead has set targets to reduce scope 1 and 2 greenhouse gas emissions 50% by 2030 (base year 2019) and achieve net-zero scope 1–3 emissions by 2040, covering manufacturing and its supply chain; in 2024 it reported a 22% reduction in scope 1–2 emissions versus 2019. Investors increasingly favor firms with clear progress toward carbon neutrality and renewable energy use—ESG-focused funds allocated over $1.5 trillion to US equities in 2024. Failure to meet these benchmarks could lower Gilead’s MSCI and Sustainalytics scores, reducing appeal to institutional investors and potentially increasing cost of capital.
Waste Management and Hazardous Material Handling
The chemical processes in Gilead’s drug manufacturing produce hazardous waste subject to EPA and EU REACH rules; in 2024 the company reported a 7% reduction in hazardous waste intensity versus 2020, aligning with regulatory limits and avoiding potential fines. Gilead’s investments in on-site treatment and a recycling program cut non-hazardous waste to landfill by 18% in 2024, lowering operational and remediation risk. Sustainable waste management is central to Gilead’s CSR, reflected in a $45 million capital allocation for environmental projects through 2025 to further reduce waste and emissions.
Water Stewardship in Biopharmaceutical Production
Biopharmaceutical manufacturing is water-intensive; Gilead reported global water withdrawal of 1.8 million cubic meters in 2024, making conservation and quality management critical environmental priorities.
Gilead must ensure sustainable sourcing and advanced treatment—especially in water-stressed regions like California and Spain where 2024 operational sites faced medium-high water risk—to avoid supply disruptions and regulatory penalties.
Improving water-use efficiency (Gilead targets 20% reduction by 2030) protects local ecosystems and strengthens long-term operational resilience, lowering utility costs and safeguarding production continuity.
Climate Change Impact on Supply Chain Resilience
Extreme weather events linked to climate change threaten Gilead's manufacturing sites and distribution, with global supply-chain disruptions causing pharma shortages in 2023–24; insurers report a 40% rise in climate-related business interruptions since 2019.
Gilead must invest in resilient infrastructure and contingency planning—diversifying suppliers, relocating critical stockpiles, and stress-testing logistics to safeguard product availability and revenue streams.
Incorporating physical climate-risk assessments into long-term strategy is essential; climate scenario analyses can quantify exposure to regional hazards and inform CAPEX and insurance budgeting.
- 40% increase in climate-related business interruptions since 2019
- Diversify suppliers and preposition stockpiles
- Stress-test logistics and include climate scenarios in CAPEX
Sustainable Packaging and Product Life Cycle
Gilead is increasing focus on recyclable and biodegradable packaging; the pharma sector saw 28% growth in sustainable packaging adoption 2023–2024, pressuring companies to act.
The company is optimizing packaging to reduce volume and waste—Gilead reported a 12% reduction target in packaging weight by 2025 in its 2024 ESG update.
Enhancing product life-cycle sustainability aligns with global trends and patient expectations; 71% of healthcare consumers prefer eco-friendly products per 2024 surveys.
- 2024: Gilead targets 12% packaging weight reduction by 2025
- Sector: 28% rise in sustainable packaging adoption (2023–2024)
- Consumer: 71% prefer eco-friendly healthcare products (2024)
Gilead aims net-zero by 2040 after 22% scope 1–2 cut; $45M capex, water & packaging targets
Gilead targets 50% scope 1–2 GHG cut by 2030 (2019 base) and net-zero scope 1–3 by 2040; 2024 showed 22% scope 1–2 reduction. 2024 water withdrawal 1.8M m3; water-risk sites in CA and Spain; 20% water-use reduction target by 2030. 2024 hazardous-waste intensity down 7% vs 2020; $45M capex to 2025 for environmental projects. Packaging weight target −12% by 2025; 2023–24 sector sustainable packaging adoption +28%.
| Metric | 2024 value |
|---|---|
| Scope 1–2 reduction vs 2019 | 22% |
| Water withdrawal | 1.8M m3 |
| Hazardous waste intensity change vs 2020 | −7% |
| Environmental capex through 2025 | $45M |
| Packaging weight target | −12% by 2025 |